Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-2407

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M ; volume:21 ; number:1 ; day:13 ; month:11 ; year:2021 ; pages:1-9 ; date:12.2021
BMC cancer ; 21, Heft 1 (13.11.2021), 1-9, 12.2021

Creator: Wang, Yurong
Zheng, Ruipan
Hu, Peizhu
Zhang, Ziheng
Shen, Shujing
Li, Xingya

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12885-021-08942-x

URN: urn:nbn:de:101:1-2022012419260857890887

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:35 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Wang, Yurong
Zheng, Ruipan
Hu, Peizhu
Zhang, Ziheng
Shen, Shujing
Li, Xingya
SpringerLink (Online service)

Other Objects (12)

EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study

Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALKfusion gene

Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations

EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study

Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALKfusion gene

Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations

EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study

Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALKfusion gene

Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

EGFR exon 20 insertion mutations in NSCLC

Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study

Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALKfusion gene

Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations

EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

EGFR exon 20 insertion mutations in NSCLC

Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study

Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALKfusion gene

Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations

EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

EGFR exon 20 insertion mutations in NSCLC

Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study

Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALKfusion gene

Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations

Related objects

Reset password